- Ponatinib for CML
- Progress in the CML Landscape
- Treatment Options
- Sequencing Treatment
- Choosing the Appropriate TKI
- Monitoring Treatment Response
- Monitoring Adherence
- Switching Therapies
- Discontinuing Treatment
- Known Factors in TKI Resistance
- Managing Adverse Events
- Allogeneic Stem Cell Transplant
- CML: On the Horizon
- The Future of CML Treatment
Chronic Myeloid Leukemia News
More Chronic Myeloid Leukemia Information
Cannabis and its synthetic cannabinoids have been studied for medicinal properties across multiple disease states.
In-human studies have evaluated the use of EOs in a supportive role, and though EOs appear to have some efficacy in this setting, larger studies are needed to confirm their effects.
Cascara use is not recommended because there are insufficient data for establishing its safety, and there have been reports of liver injury with high doses.
In vitro and in vivo data suggest that selective amino acid deprivation may have anticancer activity.
Bloodroot-containing products sold as a cure for cancer can be highly toxic and result in disfigurement.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|